Press Releases
-
ZoBio launches comprehensive DEL hit discovery service for challenging targets
Jun 14, 2026
-
Eli Lilly Launches National Sleep Apnea Awareness Campaign with Shaquille O'Neal and Zepbound
Eli Lilly has launched a nationwide awareness campaign featuring basketball legend Shaquille O'Neal to highlight the risks of moderate-to-severe obstructive sleep apnea (OSA). After learning that years of fatigue, loud snoring, and poor sleep were symptoms of OSA, O'Neal began treatment with Zepbound® (tirzepatide). The campaign encourages people experiencing sleep apnea symptoms to seek medical advice and explore treatment options. Zepbound is the first FDA-approved prescription medicine for adults with obesity and moderate-to-severe OSA, helping improve sleep quality and reduce breathing interruptions during sleep.
Jun 23, 2026
-
Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer
Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies
Jun 17, 2026
-
Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomics to Compound Screening Scale
New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates
Jun 17, 2026
-
FDA Reopens Path for UniQure’s AMT-130: 3 Years of Gene Therapy Data Could Support Huntington’s Disease Approval
UniQure plans to submit its Huntington’s disease gene therapy, AMT-130, for FDA approval after reaching agreement with the agency on using three years of clinical data. The therapy demonstrated a 75% slowdown in disease progression among patients receiving the higher dose. The development marks a major shift in the FDA’s stance following recent leadership changes and is being viewed as a positive signal for the broader cell and gene therapy sector. Following the announcement, UniQure shares surged nearly 80%, reflecting renewed investor confidence in the program and its regulatory pathway.
Jun 18, 2026
-
TrialAssure and Cancer Research UK Collaborate to Advance AI-Supported Regulatory Document Authoring
Cancer Research UK’s Centre for Drug Development is using TrialAssure LINK AI to support medical writing in CRUK-sponsored studies
Jun 17, 2026
-
Spot Biosystems Launches with $40 Million Funding and Breakthrough Non-Viral Gene Therapy for DMD
Spot Biosystems has emerged from stealth with $40 million in funding and a breakthrough non-viral gene therapy platform for Duchenne muscular dystrophy (DMD). The company demonstrated the world's first successful delivery of full-length dystrophin to human skeletal muscle using engineered extracellular vesicles (EVs). Early clinical data showed dystrophin increases of over 1,000% and 2,000% in two pediatric DMD patients, along with improved muscle function. The technology aims to overcome the limitations of traditional viral gene therapies by enabling repeat dosing and larger genetic payload delivery.
Jun 21, 2026
-
Biogen Expands Immunology Pipeline with $1 Billion RayThera Acquisition to Advance Next-Generation Therapies
Biogen has agreed to acquire RayThera in a deal worth up to $1 billion, significantly expanding its immunology pipeline and strengthening its presence in immune-mediated disease research. The acquisition brings multiple anti-inflammatory drug candidates to Biogen, including a lead therapy expected to enter Phase 1 clinical trials in Q3 2026. Once the transaction closes, Biogen will oversee the development, manufacturing, and global commercialization of these assets. The deal reflects Biogen’s long-term strategy to accelerate innovation and advance new treatment options in immunology.
Jun 17, 2026
-
Paradigm Clinical Research Opens Psychedelic Research Suite in Redding, California
Paradigm Clinical Research has opened a new psychedelic research suite at its Redding, California site, adding a purpose-built space to support psychiatric clinical trials investigating psychedelic-assisted therapies. The facility will support studies in major depressive disorder, treatment-resistant depression, PTSD, substance use disorders, and anorexia nervosa, overseen by board-certified psychiatric staff. The Redding location is notable for its access angle: Shasta County has a veteran population nearly double the state average, and recent regional health assessments have flagged behavioral health and substance use treatment as priority gaps. The company frames the expansion as part of a broader push to bring specialized psychiatric trial access to rural and underserved areas rather than concentrating it in major metro centers.
Jun 17, 2026
-
J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
J Pharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international healthcare services company, today jointly announced progress in the development of JPH203 (nanvuranlat), a novel LAT1 inhibitor for the treatment of second-line biliary tract cancer. Following alignment with the U.S. Food and Drug Administration (FDA), the program has advanced into Phase 3 clinical development and initial patients are now enrolled in the global study.
Jun 15, 2026
-
MIB Agents' Community of Families Has Awarded $2.9M in Grants to Research Pediatric Bone Cancer
Jun 15, 2026
-
Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact
Jun 15, 2026
-
Novo Nordisk Brings Weight-Loss Treatment to a New Era as Wegovy® Pill Becomes UK's First Daily GLP-1 Obesity Tablet
Novo Nordisk's Wegovy® pill has become the first daily GLP-1 weight-loss tablet approved in the UK, offering adults with obesity and overweight a convenient alternative to weekly injections. The approval was based on the Phase 3 OASIS 4 trial, where patients achieved up to 16.6% average weight loss over 64 weeks. As obesity affects around 15 million people in the UK, the launch of this oral semaglutide treatment is expected to expand access to effective obesity care and strengthen the growing role of GLP-1 drugs in long-term weight management.
Jun 15, 2026
-
Roche Secures Historic FDA Approval for First PTEN Companion Diagnostic in Prostate Cancer
Roche has received FDA approval for the VENTANA PTEN (SP218) RxDx Assay, the first companion diagnostic test designed to identify PTEN protein loss in patients with prostate adenocarcinoma. The breakthrough test helps clinicians determine which patients may benefit from AstraZeneca’s targeted therapy TRUQAP (capivasertib), advancing personalized cancer treatment. Supported by results from the CAPItello-281 clinical trial, the approval marks a significant step in precision oncology, offering new hope for patients with aggressive PTEN-deficient metastatic prostate cancer while reinforcing Roche’s leadership in companion diagnostics and personalized healthcare solutions.
Jun 14, 2026
-
Moderna and Oxford Secure $60 Million CEPI Funding to Advance Ebola Bundibugyo Vaccine Development During Congo Outbreak
CEPI has committed $60 million to accelerate Ebola Bundibugyo vaccine development with Moderna and the University of Oxford amid an ongoing outbreak in the Democratic Republic of Congo. The funding will support preclinical and early clinical development, along with manufacturing readiness for potential large-scale trials. Health agencies report 282 confirmed cases and 42 deaths, highlighting urgent containment needs. The initiative strengthens global vaccine R&D efforts focused on faster outbreak response and infectious disease preparedness.
Jun 10, 2026
-
WCG Appoints Anthony Doyle as Chief Financial Officer to Support Continued Growth and Operational Scale
WCG announced the appointment of Anthony Doyle as chief financial officer, effective June 15, 2026. Anthony brings more than two decades of financial leadership experience across healthcare, clinical research, and both public and private equity-backed organizations.
Jun 10, 2026
-
FibroFind appoints new CEO to lead firm through next phase of growth
Jun 9, 2026
-
Paradigm Clinical Research Appoints Greg Licholai, MD, Chief Medical Officer at Syneos Health, to Board of Directors
Greg Licholai, MD, Chief Medical Officer at Syneos Health, joins Board of Directors of Paradigm Clinical Research, a clinical research site organization
Jun 9, 2026
-
Alithea Genomics and Revvity Announce Distribution Agreement to Expand Access to MERCURIUSTM DRUG-seq Solutions
Alithea Genomics has announced a new agreement with Revvity Inc. to broaden access to MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions through Revvity’s global commercial network.
Jun 7, 2026
-
Roche and Nurix Place a Multi-Billion-Dollar Bet on the Future of BTK Degradation
Nurix Therapeutics and Roche have announced a global collaboration to develop and commercialize bexobrutideg, an investigational BTK degrader designed to treat blood cancers, autoimmune disorders, and neurological diseases. Under the agreement, Nurix will receive a $700 million upfront payment and could earn up to $2.3 billion in additional milestone payments. Bexobrutideg is designed to eliminate the BTK protein rather than simply block its activity, potentially offering advantages over existing BTK inhibitors, including effectiveness against treatment-resistant disease. The partnership will support ongoing late-stage studies in chronic lymphocytic leukemia (CLL) while expanding development into multiple sclerosis (MS) and chronic spontaneous urticaria (CSU), aiming to unlock the therapy’s full potential across multiple disease areas.
Jun 8, 2026


